By using this site, you agree to our Privacy Policy 

Leadership

2009 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/07/09HHS Cancels RFP for rPA Procurement and Modifies Their Approach in Favor of BAA for Development of rPA Vaccines Printer Friendly Version
12/01/09Former U.K. Health Protection Agency Director Rejoins Emergent BioSolutions to Head Biodefense Business Printer Friendly Version
11/30/09Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences Printer Friendly Version
11/13/09Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore Printer Friendly Version
11/05/09Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2009 Printer Friendly Version
11/02/09Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences Printer Friendly Version
10/14/09Emergent BioSolutions Sponsors Security and Defence Agenda Roundtable on Biopreparedness Printer Friendly Version
10/08/09Emergent BioSolutions to Release Third Quarter 2009 Financial Results and Conduct a Conference Call on November 5, 2009 Printer Friendly Version
09/30/09NIAID to Fund Development of Emergent BioSolutions' Advanced Anthrax Vaccine Candidate Printer Friendly Version
09/14/09Emergent BioSolutions Issues Statement on Court Ruling Printer Friendly Version
09/04/09Emergent BioSolutions to Webcast Presentation at Upcoming Investor Conference Printer Friendly Version
08/06/09Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2009 Printer Friendly Version
08/06/09Emergent BioSolutions Expands Manufacturing and Development Infrastructure Through a Series of Real Estate Transactions Printer Friendly Version
07/21/09Emergent BioSolutions to Release Second Quarter 2009 Financial Results and Conduct a Conference Call on August 6, 2009 Printer Friendly Version
06/18/09Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Winner in Greater Washington Printer Friendly Version
06/15/09Emergent BioSolutions Chief Financial Officer, Don Elsey, Named SmartCFO of the Year Printer Friendly Version
06/11/09Emergent BioSolutions Meets With FDA To Review Regulatory Strategy for Recombinant Anthrax Vaccine Printer Friendly Version
06/10/09Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 Years Printer Friendly Version
05/26/09Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences Printer Friendly Version
05/19/09Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday, May 21, 2009 at 10:00 am Eastern Printer Friendly Version
05/13/09Emergent BioSolutions Submits to FDA Development Plan Required of Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract with HHS Printer Friendly Version
05/08/09Emergent BioSolutions Launches BioThrax.com, an Educational Website about BioThrax (Anthrax Vaccine Adsorbed) and Anthrax Disease Printer Friendly Version
05/08/09Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Finalist in Greater Washington Printer Friendly Version
05/07/09Emergent BioSolutions Reports Financial Results for First Quarter 2009 Printer Friendly Version
05/05/09Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement with Vivalis to Explore Production Of MVA85A TB Vaccine Candidate Using EB66(R) Cell Line Printer Friendly Version
05/05/09Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement With ProBioGen To Explore Production Of MVA85A TB Vaccine Candidate Using AGE1.CR.pIX(R) Cell Line Printer Friendly Version
04/22/09HHS Extends Deadline for Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract to Submit Development Plan to FDA for Review to June 15, 2009 Printer Friendly Version
04/22/09New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa Printer Friendly Version
04/21/09Emergent BioSolutions to Release First Quarter 2009 Financial Results and Conduct a Conference Call on May 7, 2009 Printer Friendly Version
04/16/09HHS Requires Bidders in Competitive Range for Recombinant Anthrax Vaccine (rPA) Contract to Submit Development Plan to FDA for Review Printer Friendly Version
03/17/09Emergent BioSolutions Announces Commencement of Phase I/II Clinical Trial of Anthrax Immune Globulin for Treating Anthrax Disease Printer Friendly Version
03/05/09Emergent BioSolutions Reports Financial Results for Full Year 2008 Printer Friendly Version
02/27/09Emergent BioSolutions to Webcast Presentation at the Cowen & Co. 29th Annual Health Care Conference on Tuesday, March 17, 2009 Printer Friendly Version
02/12/09Emergent BioSolutions Announces That BioThrax (Anthrax Vaccine Adsorbed) Receives Market Authorization in India Printer Friendly Version
02/05/09Emergent BioSolutions to Release Full Year 2008 Financial Results and Conduct a Conference Call on March 5, 2009 Printer Friendly Version
01/09/09Emergent BioSolutions Provides Preliminary 2008 Financial Results and Guidance for 2009 Printer Friendly Version
01/08/09Emergent BioSolutions Recognized by Security Magazine Among Best Security Organizations Printer Friendly Version
01/06/09Emergent BioSolutions Ends Efforts to Acquire Protein Sciences Printer Friendly Version

Investor Toolkit